Akash Tewari
Stock Analyst at Jefferies
(2.50)
# 2,328
Out of 5,152 analysts
61
Total ratings
39.13%
Success rate
5.08%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $43.10 | -18.79% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $74.15 | +29.47% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $760.90 | +9.21% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $12.12 | +114.52% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $13.45 | -25.65% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $60.04 | +13.26% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $61.24 | +55.13% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $101.51 | +47.77% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $9.58 | +67.01% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $128.15 | +47.48% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $20.28 | +294.48% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $989.57 | +2.57% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $28.56 | +75.07% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $72.18 | +3.91% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $39.93 | -22.36% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $26.96 | +44.66% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $13.50 | +33.33% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $722.36 | -28.98% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $115.80 | +7.94% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $24.01 | -54.19% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.56 | +989.74% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $60.31 | +24.36% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $431.79 | -65.03% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $41.14 | -31.94% | 3 | Oct 7, 2021 |
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $43.10
Upside: -18.79%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $74.15
Upside: +29.47%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $760.90
Upside: +9.21%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $12.12
Upside: +114.52%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $13.45
Upside: -25.65%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $60.04
Upside: +13.26%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $61.24
Upside: +55.13%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $101.51
Upside: +47.77%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $9.58
Upside: +67.01%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $128.15
Upside: +47.48%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $20.28
Upside: +294.48%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $989.57
Upside: +2.57%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $28.56
Upside: +75.07%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $72.18
Upside: +3.91%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $39.93
Upside: -22.36%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $26.96
Upside: +44.66%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $13.50
Upside: +33.33%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $722.36
Upside: -28.98%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $115.80
Upside: +7.94%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $24.01
Upside: -54.19%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.56
Upside: +989.74%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $60.31
Upside: +24.36%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $431.79
Upside: -65.03%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $41.14
Upside: -31.94%